You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Targeting DNA Damage Response

As research advances, we continue to expand our knowledge and understanding of novel targets in DNA damage response as potential therapeutic options in oncology. While PARP inhibitors have led the way, and are increasingly being recognized as a targeted therapeutic approach for patients with BRCA mutations and other indicators of susceptibility, agents targeting different DNA damage response pathways may potentially reshape the treatment landscape in oncology in the near future.

This curriculum explores the recent clinical advances with agents targeting different aspects of DNA damage response, their rationale for use, and emerging clinical data.

Supported by an independent educational grant from


CME Activities

Biology, Rationale and Testing

Clinical Focus: Ovarian Cancer

Clinical Focus: Breast Cancer

Clinical Focus: Other Tumors

Polling Question

You must log in to answer this question
In which of the following areas would you most like to see additional education on PARP inhibitors?
Genetic counseling
Efficacy in ovarian cancer
Efficacy in breast cancer
Management of adverse events
Novel combinations with PARP inhibitors

Related Resources

Steering Committee

Johann S. de Bono, MB ChB, FRCP, MSc, PhD, FMedSci

Steering Committee Chair

Professor, Experimental Cancer Medicine; Head, Clinical Studies Division; Director, Drug Development Unit; Head, Prostate Cancer Targeted Therapy Group; Honorary Consultant, Medical Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, Surrey, England, United Kingdom

Nicoletta Colombo, MD, PhD

Professor, University of Milan-Bicocca; Director, Gynecologic Oncology Program, European Institute of Oncology, Milan, Italy

Javier Cortés, MD, PhD

Head, Breast Cancer and Gynecological Tumours, Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Karen A. Gelmon, MD, FRCPC

Professor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer Agency, Vancouver, British Columbia, Canada

Charlie Gourley, MBChB, PhD, BSc, FRCP

Professor; Chair, Medical Oncology; Honorary Consultant, Medical Oncology; Director, Nicola Murray Centre for Ovarian Cancer Research, Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, Scotland, United Kingdom